Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Evolus Q3 2026 Results: Net Loss of $12.5M, Loss Narrows

Evolus, Inc. is an aesthetic neurotoxin company that has incurred significant losses since inception and relies heavily on its licensing agreements with Daewoong and Symatese. The company is currently focused on the commercial success of Jeuveau and the regulatory approval process for its Evolysse product line.

Watch the Evolus, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue78.069.0
Gross profit50.745.8
Profit before tax-12.2-15.6
Net income-12.5-15.7
EPS (diluted, $ a share)$-0.19$-0.24

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+13.0%
Gross margin65.0%
Operating margin-10.8%
Source

10-Q filed with the SEC, NASDAQ: EOLS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Evolus, Inc.: key numbers

Share price
$6.63Close, Nov 16
Market cap
$439M
Shares outstanding
66.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Evolus, Inc.

All →
4:12 PM ET 8-K
Financial Results

Evolus Financial Results

Evolus reported Q3 2026 global net revenue of $78.0 million, a 13% increase year-over-year, driven by growth in its Jeuveau toxin and HA gel portfolio. The company achieved its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million and reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million.

Term
Q3 2026

“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company. Jeuveau® remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”

David Moatazedi, President and Chief Executive Officer

“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity. Our partnership with IBSA to develop and commercialize Profhilo® in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”

David Moatazedi, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.